Back to results

CompletedPhase 2

Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

NCT00005980

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Ludwig Boltzmann - Institute for Applied Cancer Research

Vienna, Austria

+13 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2000-04
Enrollment: 116 participants
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Purpose: treatment

Locations (14)

Ludwig Boltzmann - Institute for Applied Cancer ResearchVienna, Austria
Institut BergonieBordeaux, France
Centre Jean PerrinClermont-Ferrand, France
Institut Curie - Section MedicaleParis, France
Centre Henri BecquerelRouen, France
University of IoanninaIoannina, Greece
Rabin Medical Center - Beilinson CampusPetah Tikva, Israel
Mario Negri Institute for Pharmacological ResearchMilano (Milan), Italy
Istituti Fisioterapici Ospitalieri - RomaRome, Italy
Academisch Ziekenhuis GroningenGroningen, Netherlands
University Medical Center NijmegenNijmegen, Netherlands
Hospital Universitario 12 de OctubreMadrid, Spain
Clinique De GenolierGenolier, Switzerland
Royal Marsden NHS TrustLondon, England, United Kingdom

Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer — TrialFind